Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01417000 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2 study, sponsored by Aduro Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT01417000: Completed Phase 2 study, sponsored by Aduro Biotech.
NCT01417000 is a Phase 2 study that has completed, run by Aduro Biotech. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01417000, a Phase 2 study, has completed, sponsored by Aduro Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL CRS-207
- BIOLOGICAL GVAX Pancreas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2011-09-21 |
| Est. Completion | 2017-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01417000
The ClinicalTrials.gov registry entry for NCT01417000 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aduro Biotech, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT01417000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01417000 about?
NCT01417000 is a clinical study titled "Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer". Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer.
What is the current status of trial NCT01417000?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2011-09-21. Estimated completion is 2017-02-10.
What interventions are being tested in trial NCT01417000?
The interventions under investigation include: Cyclophosphamide (DRUG), CRS-207 (BIOLOGICAL), GVAX Pancreas (BIOLOGICAL).
Who is sponsoring clinical trial NCT01417000?
This trial is sponsored by Aduro Biotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.